Trials / Sponsors / Relay Therapeutics, Inc.
Relay Therapeutics, Inc.
Industry · 4 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor | Phase 3 | 2025-08-26 |
| Recruiting | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Over PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations | Phase 2 | 2025-06-13 |
| Completed | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer | Phase 1 | 2023-03-29 |
| Recruiting | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer | Phase 1 | 2021-12-08 |